Design and main results of the NCRI AML18 trial. Fit older patients with newly diagnosed AML (first-line treatment, 1L) and intermediate (orange) or favorable (green) cytogenetic risk or adverse cytogenetics/TP53 mutations detected later (red) were randomized 1:1 to receive standard chemotherapy induction (standard-dose cytarabine and DA) with either 1 or 2 doses of GO. Professional illustration by Patrick Lane, ScEYEnce Studios.